Phase 1 Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a confirmed grade 4 brain tumour (glioma) that has come back or gotten worse after the first round of treatment, as determined by their treating doctor
• People who have never been treated with sitagliptin or bevacizumab for this brain tumour
• People who are over 18 years old
• People who are reasonably physically functional in daily life (rated on a standard scale where 0 means fully active and 2 means capable of self-care but unable to do heavy work)
• People whose blood test results within the 21 days before joining show that the blood, liver, and kidneys are working well enough to meet the trial's specific requirements (confirm with trial site for exact values)
• People who are on blood-thinning medications (such as warfarin or low molecular weight heparin) and have no active bleeding, no high bleeding risk, and whose blood-thinning levels are stable and within the required range
• People who are able to understand and willing to sign a written consent form
• Women who could become pregnant must have a negative pregnancy test within 7 days before starting treatment, and both women who could become pregnant and men must agree to use effective contraception during the trial and for 30 days after the last dose
• People who are able to swallow whole tablets
• People whose blood pressure is controlled at or below 160/100 mmHg, with or without blood pressure medication
• People who have had a heart tracing (ECG) within 14 days before treatment showing no signs of acute heart problems
• People who have waited the required amount of time since their last treatment before starting the trial (for example, at least 4 weeks after surgery, 6 weeks after certain chemotherapy drugs called nitrosoureas, or 2 weeks after experimental therapies — exact waiting periods depend on previous treatment type)
• For the surgical part of the trial only: people who are considered suitable candidates for surgery by their medical team
• For the non-surgical part of the trial only: people who are not considered suitable candidates for surgery by their medical team

Who may not be able to join:

• People who still have significant side effects from previous treatments that have not improved to a mild level (with exceptions for hair loss and nerve-related symptoms)
• People who are currently taking part in another clinical trial using an experimental treatment
• People who have had a serious allergic reaction to medicines that are chemically similar to sitagliptin or bevacizumab
• People with serious ongoing or uncontrolled health conditions such as active infections, heart failure, unstable chest pain, irregular heartbeat, or mental health or personal circumstances that would make it difficult to follow the trial requirements
• People who are HIV-positive and on antiretroviral therapy
• People who have had another cancer in the past 2 years, with some exceptions for certain low-risk or treated cancers (confirm with trial site for specific exceptions)
• People with a significant ongoing bowel condition where diarrhoea is a major symptom, such as Crohn's disease or malabsorption
• People with a known active hepatitis B or hepatitis C infection
• People who are pregnant or breastfeeding
• People who use insulin or a type of diabetes medication called sulfonylureas
• People with a history of type 1 diabetes, poorly controlled type 2 diabetes, low blood sugar episodes that required medical treatment, or those considered by the investigators to be unsuitable for sitagliptin
• People who are unable or unwilling to swallow tablets
• People whose overall health, blood test results, or personal circumstances would, in the investigator's judgement, make participation in the trial inappropriate
• People who have had a serious artery-related event such as a heart attack, unstable chest pain, or stroke within the 6 months before signing consent
• People with a history of a blood clotting or bleeding disorder

Important: Always verify eligibility with the trial site directly before applying.